[The use of korinfar in a disorder of the patency of the bronchi and their elevated reactivity in patients with chronic kidney failure].
The author studied the effect of corinfar on bronchial patency and reactivity of the bronchi in 38 patients with chronic glomerulonephritis at the stage of chronic renal insufficiency. Age of the patients: from 26 to 48 years. Peroral administration of corinfar (dose: 10 mg) resulted in a clear improvement, mainly at the level of central bronchi, prevented the development of bronchial obstruction in the provocation test with acetylcholin, i e. possesses a protective effect. These properties of corinfar allow to recommend it for the treatment of renal insufficiency in patients showing bronchial disorders or/and bronchial hyperreactivity.
Burmak
Iu G
IuG
D000328:Adult; D001980:Bronchi / Q000187:drug effects* / Q000503:physiopathology; D001991:Bronchitis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000627:therapeutic use*; D012129:Respiratory Function Tests
D009543:Nifedipine
Primenenie korinfara pri narushenii prokhodimosti bronkhov i povyshennoĭ ikh reaktivnosti u bol'nykh s khronicheskoĭ pochechnoĭ nedostatochnosti.